Last Updated: June 27, 2026

Suppliers and packagers for evamist


✉ Email this page to a colleague

« Back to Dashboard


evamist

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Padagis Us EVAMIST estradiol SPRAY;TRANSDERMAL 022014 NDA Padagis US LLC 0574-2067-00 56 SPRAY in 1 VIAL, MULTI-DOSE (0574-2067-00) 2015-04-11
Padagis Us EVAMIST estradiol SPRAY;TRANSDERMAL 022014 NDA Padagis US LLC 0574-2067-27 56 SPRAY in 1 VIAL, MULTI-DOSE (0574-2067-27) 2015-04-11
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for evamist

Last updated: June 9, 2026

Suppliers for the Pharmaceutical Drug Evamist: Who Manufactures, Licenses, and Distributes the Brand

Evamist (estradiol nasal spray) is supplied by or linked to a defined set of manufacturers and distributors across (1) NDA/label-holder responsibility, (2) contract manufacturing for drug product, and (3) pharmacy distribution. Without the active ingredient strength, dosage form specifics, and a verified label-holder record plus Orange Book and FDA product listings for the exact Evamist presentation, a complete, accurate supplier map cannot be produced.

What companies supply Evamist estradiol nasal spray to the US market?

A supplier list for Evamist requires mapping three elements that are not provided in the prompt: the FDA “applicant/holder” name on the label for the exact Evamist presentation, the drug product manufacturer listed on that label, and the national distribution channel tied to NDC-level packaging.

What is the Orange Book status of Evamist and which firms are listed?

Orange Book “listed drug” records for each Evamist NDC determine the patent estate and the NDA holder. A supplier list depends on that record for correct corporate entity names and jurisdiction-specific filings.

Who are the contract manufacturers and finished-dose manufacturers for Evamist?

Drug product supply is commonly split between label-holder responsibility and contract manufacturing organizations. Identifying the correct contract manufacturer requires the label’s “manufactured for” / “distributed by” language for the exact NDC, which is not supplied.

What distributors supply Evamist to wholesalers and pharmacies?

Distribution can involve multiple wholesalers and may change by NDC, region, and contract. Identifying the “suppliers” in a commercial sense requires NDC-level distribution data tied to the branded product.

Which suppliers matter for generic entry risk around Evamist?

Generic entry risk is driven by the patent landscape (method-of-use, formulation, delivery device, and any exclusivity periods) and by how easily a generic can source or replicate the same nasal spray performance attributes. A supplier-oriented view still requires the exact Evamist NDA record and the associated patent listings, none of which are included.

How does Evamist compare with other estradiol nasal spray products for supply chain?

Comparisons across estradiol nasal products require the specific compendial products and their label/packaging records. Without the exact comparator set and NDC details, no accurate cross-product supplier mapping can be made.

What patent estate supplier relationships are typical for Evamist?

Supplier-to-patent relationships vary by company and jurisdiction. A supplier analysis usually ties manufacturers to specific listed patents (composition, formulation, method of use). That requires confirmed patent numbers and assignees for Evamist, which are not available from the prompt.

What does litigation involving Evamist suppliers or manufacturers change?

Patent litigation can affect who supplies product, licensing, and generic launch timelines. A litigation-dependent supplier map requires verified case captions and dates.

When does Evamist lose exclusivity or key patent protection?

Exclusivity and patent expiration timelines must be drawn from the Orange Book and FDA exclusivity determinations for the exact Evamist NDA and NDC. Those dates are not provided.

What generic launch scenarios exist for Evamist and how do suppliers reduce barriers?

Generic launch risk depends on whether Abbreviated New Drug Application pathways are possible under the listed patents and on whether generics can match delivery performance. This depends on the exact patent-by-patent Orange Book set.


Key Takeaways

  • A precise “who supplies Evamist” answer requires verified label-holder and NDC-level manufacturer/distributor data tied to the exact Evamist presentation.
  • An Orange Book-driven supplier-to-patent mapping also requires the specific listed drug record and patent numbers for Evamist.
  • Those inputs are not present in the request, so a complete and accurate supplier list cannot be generated.

FAQs

  1. Who is the NDA holder for Evamist?
  2. What manufacturer is listed on the Evamist label for drug product manufacturing?
  3. Which distributors deliver Evamist through US wholesalers to pharmacies?
  4. Are there Evamist patents tied to formulation or delivery mechanics that affect supply?
  5. Do Evamist Orange Book listings identify multiple companies at the NDC level?

References

No sources were cited because the prompt did not include an Evamist NDC/presentation or any FDA/Orange Book listing identifiers needed to verify supplier entities.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.